View ValuationiSpecimen 将来の成長Future 基準チェック /06現在、 iSpecimenの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長21.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest ResultsAug 09Consensus revenue estimates fall by 16% Mar 20Consensus estimates of losses per share improve by 15% Nov 09iSpecimen Inc. Provides Revenue Guidance for Third Quarter 2023Oct 25Consensus revenue estimates fall by 23% Aug 09Price target decreased by 38% to US$5.00 Aug 03すべての更新を表示Recent updatesiSpecimen Inc. announced delayed annual 10-K filingApr 01Ispecimen Inc. Announces Resignation of Independent Director Siyun Yang, Effective February 17, 2026Feb 26High number of new and inexperienced directors Feb 15iSpecimen Inc. announced that it expects to receive $5.5 million in fundingDec 31iSpecimen Inc., Annual General Meeting, Dec 31, 2025Nov 24iSpecimen Inc. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleNov 22iSpecimen Inc. announced delayed 10-Q filingNov 15Second quarter 2025 earnings released: US$0.42 loss per share (vs US$3.72 loss in 2Q 2024) Aug 15High number of new and inexperienced directors Aug 15iSpecimen Inc. announced that it has received $1.750127 million in fundingAug 05iSpecimen Inc. announced that it expects to receive $1.750127 million in fundingAug 01iSpecimen Inc. has completed a Follow-on Equity Offering in the amount of $3.999575 million.Jul 25iSpecimen Receives Non-Compliance Notice from Nasdaq Regarding Minimum of $2.5 Million Stockholders’ Equity RequirementJun 06iSpecimen Inc. announced delayed 10-Q filingMay 16iSpecimen Inc. has filed a Follow-on Equity Offering.May 03iSpecimen Inc. announced delayed annual 10-K filingMar 27Benign Growth For iSpecimen Inc. (NASDAQ:ISPC) Underpins Stock's 26% PlummetMar 05New major risk - Share price stability Feb 28High number of new and inexperienced directors Jan 02iSpecimen Inc. (NASDAQ:ISPC) Looks Inexpensive After Falling 38% But Perhaps Not Attractive EnoughJan 01iSpecimen Inc. Appoints Robert Bradley Lim as TreasurerJan 01Ispecimen Inc. Appoints Robert Bradley Lim as Chief Executive OfficerDec 14+ 1 more updateNew major risk - Shareholder dilution Nov 21Third quarter 2024 earnings released: US$2.10 loss per share (vs US$4.66 loss in 3Q 2023) Nov 08iSpecimen Inc. has completed a Follow-on Equity Offering in the amount of $4.999845 million.Nov 01iSpecimen Inc. has filed a Follow-on Equity Offering in the amount of $5 million.Oct 19Less than half of directors are independent Sep 30iSpecimen Inc. announced that it has received $1 million in funding from 1396974 B.C. LtdSep 26+ 1 more updateNew major risk - Revenue and earnings growth Sep 13iSpecimen Inc. (NASDAQ:ISPC) Might Not Be As Mispriced As It Looks After Plunging 32%Sep 13US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest ResultsAug 09Second quarter 2024 earnings: EPS exceeds analyst expectations Aug 07iSpecimen Inc. to Report Q2, 2024 Results on Aug 06, 2024Jul 26First quarter 2024 earnings: EPS and revenues miss analyst expectations May 08iSpecimen Inc. to Report Q1, 2024 Results on May 07, 2024Apr 27New major risk - Share price stability Apr 19Nasdaq Grants an Additional 180 Calendar Day Period, or Until October 7, 2024 to iSpecimen to Regain Compliance with the Minimum Bid Price RequirementApr 13New minor risk - Shareholder dilution Apr 01Consensus revenue estimates fall by 16% Mar 20Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 14iSpecimen Inc. to Report Fiscal Year 2023 Results on Mar 13, 2024Mar 06iSpecimen Inc. has filed a Follow-on Equity Offering in the amount of $1.5 million.Mar 05Take Care Before Diving Into The Deep End On iSpecimen Inc. (NASDAQ:ISPC)Jan 04Ispecimen Inc. Announces Executive ChangesDec 22Consensus estimates of losses per share improve by 15% Nov 09Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 03New major risk - Share price stability Nov 02iSpecimen Inc. Provides Revenue Guidance for Third Quarter 2023Oct 25iSpecimen Inc. to Report Q3, 2023 Results on Nov 02, 2023Oct 24iSpecimen Inc. Receives a Deficiency Notice from the Nasdaq Stock MarketOct 11iSpecimen Inc. Launches Next-Day Quote Service for Medical Researchers and Biospecimen ProvidersSep 29Ispecimen Expands Provider Network to Enhance Support for Women's Health ResearchSep 14iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and ProvidersAug 17Consensus revenue estimates fall by 23% Aug 09Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near TermAug 07New minor risk - Shareholder dilution Aug 04Price target decreased by 38% to US$5.00 Aug 03Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 03iSpecimen Inc. to Report Q2, 2023 Results on Aug 02, 2023Jul 26iSpecimen Inc. Receives A Letter of Resignation from Christopher Ianelli to Resign as A DirectorJul 10Less than half of directors are independent May 28First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 06Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price JumpApr 18Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 15iSpecimen Appoints Eric Langlois as Chief Revenue OfficerJan 25Secretary & Director exercised options to buy US$108k worth of stock. Jan 22iSpecimen Inc. Appoints Tracy Curley as Chief Executive OfficerJan 11Now 21% undervalued after recent price drop Dec 07iSpecimen Inc. Appoints Joseph J. Basile to Board of DirectorsDec 06Less than half of directors are independent Dec 02iSpecimen Inc. Announces Board ChangesNov 29Price target decreased to US$7.63 Nov 16Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09Price target decreased to US$7.63 Nov 08iSpecimen Inc. Launches New Open Feasibilities Dashboard on the Ispecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner NetworkOct 28iSpecimen Inc. to Report Q3, 2022 Results on Nov 08, 2022Oct 26iSpecimen Inc. Announces Executive ChangesSep 23+ 1 more updateiSpecimen names finance chief Tracy Curley as interim CEO Sep 22Consensus revenue estimates fall by 13% Aug 11iSpecimen Inc. (NASDAQ:ISPC) Analysts Just Slashed This Year's EstimatesAug 10Price target decreased to US$9.83 Aug 06Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 05Price target decreased to US$10.83 Aug 04iSpecimen GAAP EPS of -$0.30 misses by $0.02, revenue of $2.3M misses by $0.55M Aug 04iSpecimen Inc. to Report Q2, 2022 Results on Aug 04, 2022Jul 22First quarter 2022 earnings: EPS and revenues miss analyst expectations May 11iSpecimen Inc. to Report Q1, 2022 Results on May 10, 2022May 03iSpecimen Inc. Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More EfficientlyApr 27iSpecimen Inc., Annual General Meeting, May 25, 2022Apr 15iSpecimen Inc.'s (NASDAQ:ISPC) Intrinsic Value Is Potentially 69% Above Its Share PriceMar 31Founder exercised options to buy US$210k worth of stock. Mar 01Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 19iSpecimen Inc. to Report Q4, 2021 Results on Feb 17, 2022Feb 04iSpecimen Inc. announced that it has received $20.999988 million in fundingDec 03iSpecimen Inc. announced that it expects to receive $20.999988 million in fundingNov 30 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、iSpecimen は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:ISPC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20252-10-5-4N/A9/30/20253-12-8-7N/A6/30/20256-10-6-6N/A3/31/20258-11-8-7N/A12/31/20249-12-9-8N/A9/30/202410-10-6-4N/A6/30/202411-10-7-5N/A3/31/20249-12-9-5N/A12/31/202310-11-11-6N/A9/30/202310-10-12-6N/A6/30/202310-11-12-7N/A3/31/202311-10-12-7N/A12/31/202210-10-9-6N/A9/30/202210-10-9-7N/A6/30/202210-9-12-11N/A3/31/202211-7-13-12N/A12/31/202111-9-12-11N/A9/30/202111-9-10-9N/A6/30/202111-8-5-4N/A3/31/20219-7-10N/A12/31/20208-5-10N/A9/30/20207-4-2-1N/A12/31/20194-5-4-3N/A12/31/20184-5N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ISPCの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ISPCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ISPCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ISPCの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ISPCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ISPCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/05 19:53終値2026/05/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋iSpecimen Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Matthew HewittCraig-Hallum Capital Group LLCConstantine DavidesD. Boral Capital LLC.Ashok KumarThinkEquity LLC
US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest ResultsAug 09
Ispecimen Inc. Announces Resignation of Independent Director Siyun Yang, Effective February 17, 2026Feb 26
iSpecimen Receives Non-Compliance Notice from Nasdaq Regarding Minimum of $2.5 Million Stockholders’ Equity RequirementJun 06
iSpecimen Inc. (NASDAQ:ISPC) Looks Inexpensive After Falling 38% But Perhaps Not Attractive EnoughJan 01
iSpecimen Inc. announced that it has received $1 million in funding from 1396974 B.C. LtdSep 26+ 1 more update
US$3.00: That's What Analysts Think iSpecimen Inc. (NASDAQ:ISPC) Is Worth After Its Latest ResultsAug 09
Nasdaq Grants an Additional 180 Calendar Day Period, or Until October 7, 2024 to iSpecimen to Regain Compliance with the Minimum Bid Price RequirementApr 13
iSpecimen Inc. Launches Next-Day Quote Service for Medical Researchers and Biospecimen ProvidersSep 29
iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and ProvidersAug 17
Downgrade: Here's How This Analyst Sees iSpecimen Inc. (NASDAQ:ISPC) Performing In The Near TermAug 07
iSpecimen Inc. Receives A Letter of Resignation from Christopher Ianelli to Resign as A DirectorJul 10
Investors Still Aren't Entirely Convinced By iSpecimen Inc.'s (NASDAQ:ISPC) Revenues Despite 33% Price JumpApr 18
iSpecimen Inc. Launches New Open Feasibilities Dashboard on the Ispecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner NetworkOct 28
iSpecimen Inc. Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More EfficientlyApr 27